Mesenchymal stem cells (MSCs), also known as multipotent mesenchymal stromal cells, are capable of differentiation into a variety of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. MSCs have shown promise for regenerative cell therapy. For example, adipose‐derived mesenchymal stem cells (ASCs) are widely used in regenerative medicine due to their easy accessibility and abundant quantity. Indeed, ASCs are an attractive cell population for autologous cell therapy given their angiogenic, osteogenic, and immunomodulatory properties. However, the regenerative potential of ASCs isolated from patients may be hindered by the comorbidities such as obesity and metabolic syndrome. It has been shown that ASCs derived from obese animals and humans have reduced proliferative and migratory abilities and an impaired angiogenic capacity whereas they often commit to adipocyte differentiation when compared to those from non‐obese subjects . These findings suggest ASCs from obese subjects have reduced regeneration potential, and more concerning, they may promote the progression of obesity and metabolic disorders. The mechanisms for such changes of ASCs under the obese condition remain elusive.Accumulating evidence indicates that immunoregulatory effects of stem cells via paracrine signaling are as important, if not more so, as their differentiation potential in tissue regeneration . It has been
Cytometry – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud